{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-071357","form_type":"8-K","ticker":"MAZE","cik":"0001842295","company_name":"Maze Therapeutics, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.087557+00:00","generated_at":"2026-05-21T10:01:09.825376+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Maze Therapeutics Q1 net loss $32.8M; cash $294.4M; MZE829/MZE782 milestones reiterated","bullets":["Cash and cash equivalents: $294.4M at March 31, 2025, up from $196.8M at Dec 31, 2024; runway into H2 2027.","Net loss of $32.8M for Q1 2025, vs $32.5M in Q1 2024; R&D expenses $27.6M (up from $21.9M).","MZE829 Phase 2 HORIZON trial enrolling APOL1 kidney disease patients; initial proof-of-concept data expected Q1 2026.","MZE782 Phase 1 healthy volunteer trial ongoing; initial biomarker data expected Q3 2025.","Cash increase largely from IPO proceeds; no revenue reported (clinical-stage biotech)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-071357","json":"https://secwatch.observer/filing/0000950170-25-071357.json","markdown":"https://secwatch.observer/filing/0000950170-25-071357.md","text":"https://secwatch.observer/filing/0000950170-25-071357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842295/000095017025071357/0000950170-25-071357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842295/000095017025071357/maze-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T10:01:09.825376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}